Key result
Prasugrel and ticagrelor demonstrated similar ADP-induced platelet aggregation during maintenance therapy (median 15U vs 17U; p=0.370).
Why the study?
Is there a difference in platelet reactivity between patients treated with prasugrel and ticagrelor?
Observational (n=200)
Is there a difference in platelet reactivity between patients treated with prasugrel and ticagrelor?
There is a similar degree of inter-patient variability and high prevalence of low on-treatment platelet reactivity in patients treated with prasugrel and ticagrelor during the maintenance phase.
Answers are grounded in this paper and cite their sources.
Comparable maintenance platelet inhibition with prasugrel and ticagrelor; hypothesis-generating and should not yet change practice.
The aim of this study was to evaluate the distribution of platelet reactivity values in patients treated with prasugrel and ticagrelor. This prospective observational study enrolled 200 patients treated with prasugrel or ticagrelor. Platelet aggregation was determined by multiple electrode aggregometry after stimulation with adenosine diphosphate (ADP) in the maintenance phase of treatment with prasugrel or ticagrelor. Only 3% of patients in the prasugrel group and 2% of study participants in the ticagrelor group had high on treatment platelet reactivity (HTPR). The majority of patients displayed low on treatment platelet reactivity (LTPR; prasugrel: 69%; ticagrelor: 64%). The pharmacodynamic effect was similar in patients treated with prasugrel and ticagrelor: the median level of ADP-induced platelet aggregation was 15U (interquartile range IQR 9-21U) under prasugrel treatment and 17U (IQR 8-24U) under ticagrelor treatment (p=0.370). In conclusion, our study suggests that there is some degree of variability in ADP-induced platelet aggregation under treatment with prasugrel and ticagrelor.
No takes yet. Share an insight, caveat, or question.
Siller‐Matula et al. (2015) conducted an observational in Patients treated with prasugrel or ticagrelor (n=200). Prasugrel vs. Ticagrelor was evaluated on ADP-induced platelet aggregation (p=0.370). Prasugrel and ticagrelor demonstrated similar ADP-induced platelet aggregation during maintenance therapy (median 15U vs 17U; p=0.370).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: